383 related articles for article (PubMed ID: 12006513)
21. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
22. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
Schaed SG; Klimek VM; Panageas KS; Musselli CM; Butterworth L; Hwu WJ; Livingston PO; Williams L; Lewis JJ; Houghton AN; Chapman PB
Clin Cancer Res; 2002 May; 8(5):967-72. PubMed ID: 12006508
[TBL] [Abstract][Full Text] [Related]
23. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
24. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.
Norell H; Carlsten M; Ohlum T; Malmberg KJ; Masucci G; Schedvins K; Altermann W; Handke D; Atkins D; Seliger B; Kiessling R
Cancer Res; 2006 Jun; 66(12):6387-94. PubMed ID: 16778217
[TBL] [Abstract][Full Text] [Related]
25. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
27. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
Knutson KL; Disis ML
Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
[TBL] [Abstract][Full Text] [Related]
28. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
[TBL] [Abstract][Full Text] [Related]
29. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
Salazar LG; Coveler AL; Swensen RE; Gooley TA; Goodell V; Schiffman K; Disis ML
Clin Immunol; 2007 Dec; 125(3):275-80. PubMed ID: 17913588
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
32. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Kao TC; Shriver CD; Ponniah S; Peoples GE
Clin Cancer Res; 2006 Jan; 12(2):478-86. PubMed ID: 16428490
[TBL] [Abstract][Full Text] [Related]
33. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
[TBL] [Abstract][Full Text] [Related]
34. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
35. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
[TBL] [Abstract][Full Text] [Related]
36. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers.
Bharat A; Benshoff N; Fleming TP; Dietz JR; Gillanders WE; Mohanakumar T
Breast Cancer Res Treat; 2008 Aug; 110(3):453-63. PubMed ID: 17874294
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
39. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
Gritzapis AD; Fridman A; Perez SA; La Monica N; Papamichail M; Aurisicchio L; Baxevanis CN
Vaccine; 2009 Dec; 28(1):162-70. PubMed ID: 19799847
[TBL] [Abstract][Full Text] [Related]
40. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]